[go: up one dir, main page]

AR007004A1 - Sal de dihidrato de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona y composicionesfarmaceuticas que la contienen - Google Patents

Sal de dihidrato de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona y composicionesfarmaceuticas que la contienen

Info

Publication number
AR007004A1
AR007004A1 ARP970101856A ARP970101856A AR007004A1 AR 007004 A1 AR007004 A1 AR 007004A1 AR P970101856 A ARP970101856 A AR P970101856A AR P970101856 A ARP970101856 A AR P970101856A AR 007004 A1 AR007004 A1 AR 007004A1
Authority
AR
Argentina
Prior art keywords
piperazinyl
dihydro
ethyl
pharmaceutical compositions
benzoisotiazol
Prior art date
Application number
ARP970101856A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR007004A1 publication Critical patent/AR007004A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se refiere a las sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3- il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2H-indol-2-ona dihidratadas, acomposiciones farmacéuticas que contienen dichas sales metanosulfonato hidratadas. La fig.1representa el espectro de difracción de polvo de rayos Xde metanosulfonato de ziprasidona dihidratado (cristal alargado) expresado como la intensidad (Cps) frente al ángulo de difracción (grados 20).
ARP970101856A 1996-05-07 1997-05-05 Sal de dihidrato de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona y composicionesfarmaceuticas que la contienen AR007004A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
AR007004A1 true AR007004A1 (es) 1999-10-13

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101856A AR007004A1 (es) 1996-05-07 1997-05-05 Sal de dihidrato de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona y composicionesfarmaceuticas que la contienen

Country Status (40)

Country Link
US (1) US6245765B1 (es)
EP (1) EP0918772B1 (es)
JP (1) JP3494659B2 (es)
KR (1) KR100333215B1 (es)
CN (1) CN1091769C (es)
AP (1) AP765A (es)
AR (1) AR007004A1 (es)
AT (1) ATE278689T1 (es)
AU (1) AU731267B2 (es)
BG (1) BG63544B1 (es)
BR (1) BR9709889A (es)
CA (1) CA2252898C (es)
CO (1) CO4940466A1 (es)
CZ (1) CZ289215B6 (es)
DE (1) DE69731094T2 (es)
DK (1) DK0918772T3 (es)
DZ (1) DZ2222A1 (es)
EA (1) EA001190B1 (es)
EG (1) EG24076A (es)
ES (1) ES2229342T3 (es)
GT (1) GT199700052A (es)
HR (1) HRP970236B1 (es)
ID (1) ID16867A (es)
IL (1) IL126591A (es)
IS (1) IS2080B (es)
MA (1) MA24171A1 (es)
MY (1) MY119997A (es)
NO (1) NO312514B1 (es)
NZ (1) NZ332218A (es)
OA (1) OA10909A (es)
PL (1) PL188330B1 (es)
PT (1) PT918772E (es)
SI (1) SI0918772T1 (es)
SK (1) SK282837B6 (es)
TN (1) TNSN97074A1 (es)
TR (1) TR199802240T2 (es)
TW (1) TW491847B (es)
UA (1) UA46840C2 (es)
WO (1) WO1997042191A1 (es)
ZA (1) ZA973876B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
WO2001091756A2 (en) * 2000-06-02 2001-12-06 Pfizer Products Inc. S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
AU2004237951A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
EP1530570A2 (en) * 2003-06-03 2005-05-18 Teva Pharmaceutical Industries Limited CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
WO2005040160A2 (en) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
CA2565996A1 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
ES2526092T3 (es) * 2004-11-16 2015-01-05 Alkermes Pharma Ireland Limited Formulaciones de olanzapina en nanopartículas inyectables
WO2006086787A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Process of preparing ziprasidone mesylate
WO2006086779A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Amorphous ziprasidone mesylate
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
EP2146577A1 (en) * 2007-05-18 2010-01-27 Scidose, Llc Ziprasidone formulations
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
KR101936968B1 (ko) * 2010-10-18 2019-01-09 다이닛본 스미토모 세이야꾸 가부시끼가이샤 주사용 서방형 제제
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
HU229057B1 (en) 1996-05-07 2013-07-29 Pfizer Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist

Also Published As

Publication number Publication date
AP765A (en) 1999-09-17
CZ289215B6 (cs) 2001-12-12
DE69731094T2 (de) 2006-02-23
ES2229342T3 (es) 2005-04-16
SK282837B6 (sk) 2002-12-03
CN1216991A (zh) 1999-05-19
AU2174797A (en) 1997-11-26
EG24076A (en) 2008-05-11
BR9709889A (pt) 1999-08-10
NO985194D0 (no) 1998-11-06
UA46840C2 (uk) 2002-06-17
EP0918772A1 (en) 1999-06-02
AP9700976A0 (en) 1997-07-31
TNSN97074A1 (fr) 2005-03-15
PL188330B1 (pl) 2005-01-31
HRP970236B1 (en) 2002-12-31
HK1017892A1 (en) 1999-12-03
DZ2222A1 (fr) 2002-12-03
IL126591A0 (en) 1999-08-17
PT918772E (pt) 2004-12-31
CO4940466A1 (es) 2000-07-24
DE69731094D1 (de) 2004-11-11
SI0918772T1 (en) 2005-02-28
CZ349398A3 (cs) 1999-09-15
PL329884A1 (en) 1999-04-12
HRP970236A2 (en) 1998-06-30
BG102892A (en) 1999-09-30
AU731267B2 (en) 2001-03-29
EA001190B1 (ru) 2000-12-25
JP3494659B2 (ja) 2004-02-09
CA2252898C (en) 2003-04-08
MY119997A (en) 2005-08-30
CN1091769C (zh) 2002-10-02
EA199800912A1 (ru) 1999-04-29
DK0918772T3 (da) 2005-01-10
SK150898A3 (en) 2000-02-14
OA10909A (en) 2001-10-26
MA24171A1 (fr) 1997-12-31
KR100333215B1 (ko) 2002-06-20
BG63544B1 (bg) 2002-04-30
WO1997042191A1 (en) 1997-11-13
IS4874A (is) 1998-10-20
ID16867A (id) 1997-11-20
IS2080B (is) 2006-02-15
US6245765B1 (en) 2001-06-12
KR20000010824A (ko) 2000-02-25
JPH11509867A (ja) 1999-08-31
EP0918772B1 (en) 2004-10-06
GT199700052A (es) 2001-08-29
NZ332218A (en) 2005-02-25
ZA973876B (en) 1998-11-06
NO312514B1 (no) 2002-05-21
CA2252898A1 (en) 1997-11-13
TR199802240T2 (es) 1999-02-22
IL126591A (en) 2001-11-25
TW491847B (en) 2002-06-21
NO985194L (no) 1998-11-06
ATE278689T1 (de) 2004-10-15

Similar Documents

Publication Publication Date Title
AR007004A1 (es) Sal de dihidrato de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona y composicionesfarmaceuticas que la contienen
ES2146300T3 (es) Utilizacion de composiciones antihelminticas para el tratamiento de infecciones causadas por anoplocephala perfoliata en equidos.
UY29182A1 (es) "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones"
CO5271691A1 (es) Nuevos compuestos
HN2009001145A (es) Compuestos y composiciones como inhibidores de proteina quinasa
ATE262519T1 (de) Heterozyklische ether- und thioether-verbindungen,verwendbar zur steuerung von chemischer synaptischer transmission
DK0934937T3 (da) Azolderivater som superoxidradikalinhibitor
NO924696L (no) Fremgangsmaate for fremstilling av oksazolidinon- og tiazolidinon-derivater
AR029570A1 (es) Nueva forma cristalina gamma de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
ECSP045221A (es) Sales de valsartan
AU2003259521A1 (en) Combination of a) n-{5-(4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
ES2167931T3 (es) Derivados bifenilicos sustituidos por un radical aromatico o heteroaromatico y composiciones farmaceuticas y cosmeticas que los contienen.
ES2108422T3 (es) Combinaciones sinergicas de productos antisolares y composiciones cosmeticas y dermatologicas que las contienen.
BR0313684A (pt) Aparelho de maquiagem
SV2007002526A (es) Diarilsulfona sulfonamidas y el uso de las mismas ref. p1018
ES2180573T3 (es) Uso de derivados de indol como antagonistas de 5ht1.
ES2108482T3 (es) Productos solidos de cloruro de mepicuato y cloruro de clormecuato altamente concentrados.
BR0109483A (pt) Pró-drogas de derivados de imidazopiridina
ES2092868T3 (es) Utilizacion de derivados de la 4-tiorresorcina en unas composiciones cosmeticas o dermofarmaceuticas de accion despigmentante.
SE8304408L (sv) Desoxiuridinderivat, forfaranden for deras framstellning och deras anvendning som lekemedel
UY29181A1 (es) Derivados de bencenosulfonamidas n-sustituidos, composiciones que los contienen, procesos de preparación y aplicaciones
DE69726206D1 (de) Prodrogen von 5-(2-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-on
BR9806193A (pt) Composição bi-aromáticos ligados por um radical heteroetinileno e composições farmacêuticas e cosméticas que os contêm
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables